Wells Fargo & Company Forecasts Strong Price Appreciation for Centene (NYSE:CNC) Stock

Centene (NYSE:CNC – Get Free Report) had its target price raised by analysts at Wells Fargo & Company from $69.00 to $75.00 in a note issued to investors on Friday, Benzinga reports. The firm presently has an “equal weight” rating on the stock. Wells Fargo & Company‘s price target suggests a potential upside of 9.62% from the company’s previous close.

Several other research firms have also commented on CNC. JPMorgan Chase & Co. lifted their price target on shares of Centene from $67.00 to $75.00 and gave the company a “neutral” rating in a report on Thursday. Weiss Ratings raised shares of Centene from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday. Royal Bank Of Canada raised their target price on shares of Centene from $70.00 to $71.00 and gave the stock a “sector perform” rating in a report on Thursday, July 9th. Zacks Research downgraded Centene from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 5th. Finally, TD Cowen reaffirmed a “hold” rating and set a $65.00 target price (up from $47.00) on shares of Centene in a report on Tuesday, July 14th. Nine investment analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $73.60.

View Our Latest Research Report on CNC

Centene Stock Performance

CNC stock opened at $68.42 on Friday. The stock’s 50 day simple moving average is $66.09 and its 200 day simple moving average is $55.26. Centene has a 12-month low of $31.63 and a 12-month high of $72.50. The firm has a market cap of $33.87 billion, a P/E ratio of 23.43, a P/E/G ratio of 0.40 and a beta of 1.13. The company has a current ratio of 1.16, a quick ratio of 1.15 and a debt-to-equity ratio of 0.69.

Centene (NYSE:CNC – Get Free Report) last released its quarterly earnings data on Tuesday, October 27th. The company reported $0.58 EPS for the quarter, topping analysts’ consensus estimates of $0.10 by $0.48. Centene had a net margin of 0.72% and a return on equity of 12.15%. The firm had revenue of $50.65 billion during the quarter, compared to the consensus estimate of $47.12 billion. During the same quarter in the previous year, the company posted $0.50 earnings per share. The firm’s revenue was up 1.9% on a year-over-year basis. As a group, equities research analysts predict that Centene will post 5.24 EPS for the current year.

Insider Activity

In other news, General Counsel Christopher Koster sold 56,500 shares of the stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $66.90, for a total value of $3,779,850.00. Following the completion of the transaction, the general counsel directly owned 248,854 shares in the company, valued at $16,648,332.60. This trade represents a 18.50% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 0.37% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Citizens Financial Group Inc. RI increased its stake in Centene by 71.5% in the 3rd quarter. Citizens Financial Group Inc. RI now owns 41,815 shares of the company’s stock valued at $2,598,000 after buying an additional 17,429 shares during the period. Deutsche Bank AG acquired a new position in Centene during the 2nd quarter valued at $257,279,000. Hara Capital LLC acquired a new stake in shares of Centene during the 2nd quarter worth approximately $5,222,000. Paralel Advisors LLC acquired a new position in Centene in the second quarter worth about $4,531,000. Finally, Roberts Glore & Co. Inc. IL acquired a new stake in shares of Centene in the 2nd quarter valued at $1,659,000. Institutional investors and hedge funds own 93.63% of the company’s stock.

Key Headlines Impacting Centene

Here are the key news stories impacting Centene this week:

  • Positive Sentiment: Analysts continue to raise price targets. Wells Fargo lifted its target from $69 to $75 while maintaining an “equal weight” rating. JPMorgan also raised its target from $67 to $75, and UBS increased its target from $70 to $78. These revisions suggest analysts see additional value after Centene’s earnings update, even though the ratings remain cautious. Wells Fargo analyst update JPMorgan analyst update UBS analyst update
  • Positive Sentiment: Strong quarterly results and higher guidance support the stock. Centene exceeded earnings and revenue expectations, and its quarterly revenue increased year over year. The company’s guidance increase reinforces expectations for improved profitability and prompted additional analyst optimism. Centene Q3 earnings and guidance Centene guidance increase
  • Neutral Sentiment: Analyst ratings remain restrained. Wells Fargo and UBS retain “equal weight” or “neutral” recommendations, indicating that the higher targets reflect moderate appreciation potential rather than a strong conviction that CNC is significantly undervalued. Centene analyst price target update
  • Negative Sentiment: Membership pressure remains a key risk. Coverage has highlighted lingering membership challenges and uncertainty over whether Centene can maintain a stable health benefits ratio. These issues could offset the benefit of stronger earnings and guidance if they pressure margins or future revenue growth. Centene membership pressures Centene health benefits ratio analysis

Centene Company Profile

(Get Free Report)

Centene Corporation is a diversified healthcare enterprise that provides government-sponsored and commercial health insurance programs and related healthcare services. The company’s offerings are primarily focused on Medicaid, Medicare, and health insurance marketplace plans, with an emphasis on serving individuals and families who may have limited access to traditional healthcare coverage.

Centene operates Medicaid health plans through state-based contracts and offers Medicare Advantage, Medicare prescription drug, and Medicare Supplement products through its Wellcare brand.

Featured Articles

Analyst Recommendations for Centene (NYSE:CNC)

Receive News & Ratings for Centene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centene and related companies with MarketBeat.com's FREE daily email newsletter.